Clinical Trial Update: Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating amrubicin in patients with small cell lung cancer refractory or progressing after prior therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Amrubicin (amrubicin)

Snippet

Sponsor: Celgene | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED